Watch part one of the webinar
Watch part two of the webinar
Per Anton Sirnes and Antonio Coca
For the best learning experience, we recomment to read the ESC Guidelines on Arterial Hypertension (Management of)
The faculty will discuss the following issues:
- To review the evidence and recommendations for silent organ damage evaluation in patients with hypertension
- To discuss the usefulness of the “Table of total cardiovascular risk stratification” of the ESH/ESC 2013 Guidelines
- To discuss and review the recommendations for the best antihypertensive therapeutic strategy in specific groups of patients at high risk
The ESC Webinars are designed to help you improve your daily practice!
The format includes a case based presentation, online assessment and live discussions with the 2 key opinion leaders who will give you some useful tips for your daily clinical practice.
Your questions answered by Professor Antonio Coca
- Would lowering high-normal BP (e.g. 138/88) to normal BP (< 130/80) by non-pharmaceutical means results in lower CV events?
- Is a beta-blocking agent better for a patient with hypertension AND a high resting heart rate or abnormal rate recovery ?
- Pshychotherapeutic methods how often they are used for AH prevention
- Night hypersympathetic activity obtain from HRV (Holter) what is the place for this method
- Taking into account results of Simplisity HTN-3 are u plan to make change in Guidelines 2013?
- If a patient is already on ACE and ARB and his BP is well controlled should we alter the treatment? thank you.
- Why an evenig dose insteed of a morning dose
- Why exactly Lercanidipine is preferred here over diuretic in combination with ACE-inh?
- Should the patient be prescribed with aspirin as well because of the carotid disease? Thank you.
- Because this is a high risk patient don't we need a higher dose of Statine (like Atorvastatine 40mg)?
- Is it better to give all the agents concominantly eg in the morning or to use one agent in the morning and the other in the evening?
- This patient is also obese with BMI> 31. So I think it is important to associate to drug therapy proper hygienic-dietary lifestyle ie physical exercise and proper dietary regimen to lower its level of risk. What do you think about?
- If patient with AH due to nephritis with proteinuria 30 MG|DL with CrCR- 65 ml/min is taking combo Amlo+Ramipril with BP 150/93 mmHg what level of BP is recommended in this case?
- Why this 2 patients in your cases began their treament with ARB?
- Does INDAPAMIDE have any pharmacological superiority to other diuretic drugs in its class - and under what circumstances?
- Diuretics will increase erectile disfnction
- The dose of statine should not be higher because this is a high risk patient?
- What is your opinion in adding aspirin in this second case?
- Is the addition of aspirin in these cases recommended?
- When is the aspirin a good idea?
Your questions answered by Dr Per Anton Sirnes
- how to control the systolic hypertension with normal diastolic pressure?
- when systolic pressure normal and diastolic hypertensive pressure. with atrial fibrillation?
- why hypertension not be hypotension in left ventricle?
- systolic hypertension how to control ?
- Role of speckle tracking echocardiography in assessment of patients with hypertension?
- what are the risks of hypertension?
- If on the amb. bp measurement we find few readings of around 170/115 and the average is normal how we interprete the test
- CCB have side effects as legs' edema and tachycardia that strongly limit their use.
- Go back to the ECG: there to me there are sign of LVH and you already knew that tyhe patient was at higher risk.
- What about the role of beta blockers in reduction of Aortic dilatation?
- what would you suggest on Asian decent with uncontrolled HTN and of moderate risk?? combi meds
- Why an evenig dose insteed of a morning dose
This programme is supported by Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb and Pfizer Alliance, Daiichi Sankyo Europe GmbH, Novartis Pharma AG and SERVIER in the form of unrestricted educational grants. The scientific programme has not been influenced in any way by its sponsors.